Evaluation of New Tc-99m-labeled Arg-X-Asp-conjugated α-melanocyte Stimulating Hormone Peptides for Melanoma Imaging

Overview

Journal Mol Pharm

Publisher American Chemical Society

Specialty Pharmacology

Date 2013 Jul 27

PMID 23885640

Citations 9

Authors

Adam M Flook

Jianquan Yang

Yubin Miao

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to examine the melanoma targeting and imaging properties of two new (99m)Tc-labeled Arg-X-Asp-conjugated α-melanocyte stimulating hormone (α-MSH) peptides. RTD-Lys-(Arg(11))CCMSH {c[Asp-Arg-Thr-Asp-DTyr]-Lys-Cys-Cys-Glu-His-DPhe-Arg-Trp-Cys-Arg-Pro-Val-NH2} and RVD-Lys-(Arg(11))CCMSH peptides were synthesized, and their melanocortin-1 (MC1) receptor binding affinities were determined in B16/F1 melanoma cells. The biodistribution and melanoma imaging properties of (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH were determined in B16/F1 melanoma-bearing C57 mice. The IC50 values of RTD-Lys-(Arg(11))CCMSH and RVD-Lys-(Arg(11))CCMSH were 0.7 ± 0.07 and 1.0 ± 0.3 nM in B16/F1 melanoma cells. Both (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH displayed high melanoma uptake. (99m)Tc-RTD-Lys-(Arg(11))CCMSH exhibited the highest tumor uptake of 18.77 ± 5.13% ID/g at 2 h postinjection, whereas (99m)Tc-RVD-Lys-(Arg(11))CCMSH reached the highest tumor uptake of 19.63 ± 4.68% ID/g at 4 h postinjection. Both (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH showed low accumulation in normal organs (<1.7% ID/g) except for the kidneys at 2 h postinjection. The renal uptake of (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH was 135.14 ± 23.62 and 94.01 ± 18.31% ID/g at 2 h postinjection, respectively. The melanoma lesions were clearly visualized by single-photon emission computed tomography (SPECT)/CT using either (99m)Tc-RTD-Lys-(Arg(11))CCMSH or (99m)Tc-RVD-Lys-(Arg(11))CCMSH as an imaging probe at 2 h postinjection. Overall, the introduction of Thr or Val residue retained high melanoma uptake of (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH. However, high renal uptake of (99m)Tc-RTD-Lys-(Arg(11))CCMSH and (99m)Tc-RVD-Lys-(Arg(11))CCMSH need to be reduced to facilitate their future applications.

Citing Articles

Elevating theranostics: The emergence and promise of radiopharmaceutical cell-targeting heterodimers in human cancers.

Chambers C, Chitwood B, Smith C, Miao Y iRadiology. 2024; 2(2):128-155.

PMID: 38708130 PMC: 11067702. DOI: 10.1002/ird3.62.

Metformin Reduces Renal Uptake of Radiotracers and Protects Kidneys from Radiation-Induced Damage.

Xiong C, Yin D, Li J, Huang Q, Ravoori M, Kundra V Mol Pharm. 2019; 16(2):808-815.

PMID: 30608713 PMC: 6727202. DOI: 10.1021/acs.molpharmaceut.8b01091.

Molecular Imaging and Radionuclide Therapy of Melanoma Targeting the Melanocortin 1 Receptor.

Zhang C, Lin K, Benard F Mol Imaging. 2017; 16:1536012117737919.

PMID: 29182034 PMC: 5714078. DOI: 10.1177/1536012117737919.

PET and SPECT imaging of melanoma: the state of the art.

Wei W, Ehlerding E, Lan X, Luo Q, Cai W Eur J Nucl Med Mol Imaging. 2017; 45(1):132-150.

PMID: 29085965 PMC: 5700861. DOI: 10.1007/s00259-017-3839-5.

Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.

Lindegren S, Andrade L, Back T, Machado C, Horta B, Buchpiguel C PLoS One. 2015; 10(5):e0126298.

PMID: 25970341 PMC: 4430291. DOI: 10.1371/journal.pone.0126298.

References

Guo H, Yang J, Gallazzi F, Miao Y . Effects of the amino acid linkers on the melanoma-targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-MSH peptides. J Nucl Med. 2011; 52(4):608-16. PMC: 3065533. DOI: 10.2967/jnumed.110.086009. View

Decristoforo C, Faintuch-Linkowski B, Rey A, von Guggenberg E, Rupprich M, Hernandez-Gonzales I . [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Nucl Med Biol. 2006; 33(8):945-52. DOI: 10.1016/j.nucmedbio.2006.09.001. View

Miao Y, Whitener D, Feng W, Owen N, Chen J, Quinn T . Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem. 2003; 14(6):1177-84. DOI: 10.1021/bc034069i. View

Decristoforo C, Gonzalez I, Carlsen J, Rupprich M, Huisman M, Virgolini I . 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2008; 35(8):1507-15. DOI: 10.1007/s00259-008-0757-6. View

Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M . A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004; 45(1):116-23. View

Yang J, Miao Y . Substitution of Gly with Ala enhanced the melanoma uptake of technetium-99m-labeled Arg-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptide. Bioorg Med Chem Lett. 2012; 22(4):1541-5. PMC: 3274613. DOI: 10.1016/j.bmcl.2012.01.003. View

Giblin M, Wang N, Hoffman T, Jurisson S, Quinn T . Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A. 1998; 95(22):12814-8. PMC: 23606. DOI: 10.1073/pnas.95.22.12814. View

Li C, Wang W, Wu Q, Ke S, Houston J, Sevick-Muraca E . Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol. 2006; 33(3):349-58. DOI: 10.1016/j.nucmedbio.2006.01.001. View

Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G . Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med. 2004; 45(5):892-902. View

10.

Miao Y, Benwell K, Quinn T . 99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med. 2007; 48(1):73-80. View

11.

Cheng Z, Xiong Z, Subbarayan M, Chen X, Gambhir S . 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem. 2007; 18(3):765-72. PMC: 4143155. DOI: 10.1021/bc060306g. View

12.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

13.

Wei L, Butcher C, Miao Y, Gallazzi F, Quinn T, Welch M . Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med. 2007; 48(1):64-72. View

14.

Miao Y, Figueroa S, Fisher D, Moore H, Testa R, Hoffman T . 203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med. 2008; 49(5):823-9. PMC: 3610567. DOI: 10.2967/jnumed.107.048553. View

15.

Guo H, Yang J, Gallazzi F, Miao Y . Reduction of the ring size of radiolabeled lactam bridge-cyclized alpha-MSH peptide, resulting in enhanced melanoma uptake. J Nucl Med. 2010; 51(3):418-26. PMC: 2998183. DOI: 10.2967/jnumed.109.071787. View

16.

Hultsch C, Schottelius M, Auernheimer J, Alke A, Wester H . (18)F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK). Eur J Nucl Med Mol Imaging. 2009; 36(9):1469-74. DOI: 10.1007/s00259-009-1122-0. View

17.

Yang J, Guo H, Miao Y . Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging. Nucl Med Biol. 2010; 37(8):873-83. PMC: 2993178. DOI: 10.1016/j.nucmedbio.2010.05.006. View

18.

Guo H, Shenoy N, Gershman B, Yang J, Sklar L, Miao Y . Metastatic melanoma imaging with an (111)In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide. Nucl Med Biol. 2009; 36(3):267-76. PMC: 2685149. DOI: 10.1016/j.nucmedbio.2009.01.003. View

19.

Alves S, Correia J, Gano L, Rold T, Prasanphanich A, Haubner R . In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys). Bioconjug Chem. 2007; 18(2):530-7. DOI: 10.1021/bc060234t. View

20.

Wei L, Ye Y, Wadas T, Lewis J, Welch M, Achilefu S . (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nucl Med Biol. 2009; 36(3):277-85. PMC: 2692938. DOI: 10.1016/j.nucmedbio.2008.12.008. View